Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future - 05/02/16
Abstract |
In the past, the development of more effective, safe, convenient, broadly applicable, and easy to manufacture vaccines for allergen-specific immunotherapy (AIT) has been limited by the poor quality of natural allergen extracts. Progress made in the field of molecular allergen characterization has now made it possible to produce defined vaccines for AIT and eventually for preventive allergy vaccination based on recombinant DNA technology and synthetic peptide chemistry. Here we review the characteristics of recombinant and synthetic allergy vaccines that have reached clinical evaluation and discuss how molecular vaccine approaches can make AIT more safe and effective and thus more convenient. Furthermore, we discuss how new technologies can facilitate the reproducible manufacturing of vaccines of pharmaceutical grade for inhalant, food, and venom allergens. Allergy vaccines in clinical trials based on recombinant allergens, recombinant allergen derivatives, and synthetic peptides allow us to target selectively different immune mechanisms, and certain of those show features that might make them applicable not only for therapeutic but also for prophylactic vaccination.
Le texte complet de cet article est disponible en PDF.Key words : Allergy, allergen, allergen-specific immunotherapy, allergy vaccine, preventive allergy vaccine
Abbreviation used : AIT
Plan
This study was supported by research grants F4605 and F4613 from the Austrian Science Fund (FWF) and by a research grant from BIOMAY AG, Vienna, Austria. |
|
Disclosure of potential conflict of interest: R. Valenta has received grants and consulting fees or honoraria from Biomay AG, ThermoFisher, and Fresenius Medical Care. V. Niederberger has received a grant from the Austrian Science Fund (FWF; SFB4613). The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 137 - N° 2
P. 351-357 - février 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?